Score Pharma
  • Home
  • About Us
  • Platform
  • Pipeline
  • Investors & Media
  • More
    • Home
    • About Us
    • Platform
    • Pipeline
    • Investors & Media
Score Pharma
  • Home
  • About Us
  • Platform
  • Pipeline
  • Investors & Media

Enhanced Antibody Therapeutics

Enhanced Antibody TherapeuticsEnhanced Antibody TherapeuticsEnhanced Antibody Therapeutics

Next Generation ADCC Enhancement With CoreX Platform Technology

Enhanced Antibody Therapeutics

Enhanced Antibody TherapeuticsEnhanced Antibody TherapeuticsEnhanced Antibody Therapeutics

Next Generation ADCC Enhancement With CoreX Platform Technology

What We Do

Medical Need

Improved Time-to-Market

Initial Disease Focus

We are developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response.

Initial Disease Focus

Improved Time-to-Market

Initial Disease Focus

Our team is prioritizing cancer therapies such as non-Hodgkin lymphoma (NHL),   

Chronic Lymphocytic Leukemia (CLL), and HER2-positive breast cancer.

Improved Time-to-Market

Improved Time-to-Market

Improved Time-to-Market

 We are a therapeutic start-up based on a platform technology, radically de-risking drug discovery and development.

Contact Score

A Virtual Biotech Based In Alabama

With roots in Huntsville, Alabama, Score Pharma relies on strategic partnerships, dedicated Alabama resources, and a distributed virtual team to bring innovation to existing therapies. Contact us to learn more about how you may become a part of this exciting initiative to improve patient health.

contact@scorepharma.com

Copyright © 2024 Score Pharma, Inc. - All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept